Search alternatives:
largest decrease » largest decreases (Expand Search), larger decrease (Expand Search), marked decrease (Expand Search)
linear decrease » linear increase (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
i largest » _ largest (Expand Search), i large (Expand Search)
largest decrease » largest decreases (Expand Search), larger decrease (Expand Search), marked decrease (Expand Search)
linear decrease » linear increase (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
i largest » _ largest (Expand Search), i large (Expand Search)
-
1301
Image_8_Orexin-A Exerts Neuroprotective Effects via OX1R in Parkinson’s Disease.TIF
Published 2018“…The upregulation of BDNF is mainly concerned with PI3K and PKC signaling pathways via OX1R. The present study demonstrated that orexin-A exerted neuroprotective effects on MPTP parkinsonian mice, which may imply orexin-A as a potential therapeutic target for PD.…”
-
1302
Image_7_Orexin-A Exerts Neuroprotective Effects via OX1R in Parkinson’s Disease.TIF
Published 2018“…The upregulation of BDNF is mainly concerned with PI3K and PKC signaling pathways via OX1R. The present study demonstrated that orexin-A exerted neuroprotective effects on MPTP parkinsonian mice, which may imply orexin-A as a potential therapeutic target for PD.…”
-
1303
Image_4_Orexin-A Exerts Neuroprotective Effects via OX1R in Parkinson’s Disease.TIF
Published 2018“…The upregulation of BDNF is mainly concerned with PI3K and PKC signaling pathways via OX1R. The present study demonstrated that orexin-A exerted neuroprotective effects on MPTP parkinsonian mice, which may imply orexin-A as a potential therapeutic target for PD.…”
-
1304
Image_6_Orexin-A Exerts Neuroprotective Effects via OX1R in Parkinson’s Disease.TIF
Published 2018“…The upregulation of BDNF is mainly concerned with PI3K and PKC signaling pathways via OX1R. The present study demonstrated that orexin-A exerted neuroprotective effects on MPTP parkinsonian mice, which may imply orexin-A as a potential therapeutic target for PD.…”
-
1305
Image_5_Orexin-A Exerts Neuroprotective Effects via OX1R in Parkinson’s Disease.TIF
Published 2018“…The upregulation of BDNF is mainly concerned with PI3K and PKC signaling pathways via OX1R. The present study demonstrated that orexin-A exerted neuroprotective effects on MPTP parkinsonian mice, which may imply orexin-A as a potential therapeutic target for PD.…”
-
1306
Image_10_Orexin-A Exerts Neuroprotective Effects via OX1R in Parkinson’s Disease.TIF
Published 2018“…The upregulation of BDNF is mainly concerned with PI3K and PKC signaling pathways via OX1R. The present study demonstrated that orexin-A exerted neuroprotective effects on MPTP parkinsonian mice, which may imply orexin-A as a potential therapeutic target for PD.…”
-
1307
Image_1_Orexin-A Exerts Neuroprotective Effects via OX1R in Parkinson’s Disease.TIF
Published 2018“…The upregulation of BDNF is mainly concerned with PI3K and PKC signaling pathways via OX1R. The present study demonstrated that orexin-A exerted neuroprotective effects on MPTP parkinsonian mice, which may imply orexin-A as a potential therapeutic target for PD.…”
-
1308
Image_2_Orexin-A Exerts Neuroprotective Effects via OX1R in Parkinson’s Disease.TIF
Published 2018“…The upregulation of BDNF is mainly concerned with PI3K and PKC signaling pathways via OX1R. The present study demonstrated that orexin-A exerted neuroprotective effects on MPTP parkinsonian mice, which may imply orexin-A as a potential therapeutic target for PD.…”
-
1309
Image_3_Orexin-A Exerts Neuroprotective Effects via OX1R in Parkinson’s Disease.TIF
Published 2018“…The upregulation of BDNF is mainly concerned with PI3K and PKC signaling pathways via OX1R. The present study demonstrated that orexin-A exerted neuroprotective effects on MPTP parkinsonian mice, which may imply orexin-A as a potential therapeutic target for PD.…”
-
1310
Image_9_Orexin-A Exerts Neuroprotective Effects via OX1R in Parkinson’s Disease.TIF
Published 2018“…The upregulation of BDNF is mainly concerned with PI3K and PKC signaling pathways via OX1R. The present study demonstrated that orexin-A exerted neuroprotective effects on MPTP parkinsonian mice, which may imply orexin-A as a potential therapeutic target for PD.…”
-
1311
-
1312
Raw data.
Published 2024“…<div><p>Hamstring injuries are associated with decreased hamstring strength. Matinlauri et al.’s 90:20 Isometric Posterior Chain Test (90:20 IPCT) efficiently assesses hamstring strength, but has not been validated so far. …”
-
1313
-
1314
OP50 <i>E. coli</i>-fed nematodes are generally healthy while pathogen-fed worms demonstrate a decrease in overall health.
Published 2014“…Double mutant <i>ogt-1; pmk-1</i> animals exhibit the largest decrease in pumping rate. …”
-
1315
-
1316
The G Protein-Coupled Receptor RAI3 Is an Independent Prognostic Factor for Pancreatic Cancer Survival and Regulates Proliferation via STAT3 Phosphorylation
Published 2017“…Especially the loss of apical RAI3 expression represents an independent prognostic parameter for overall survival of patients with pancreatic cancer. Suppression of GPRC5a results in decreased cell growth, proliferation and migration in pancreatic cancer cell lines via a STAT3 modulated pathway, independent from ERK activation.…”
-
1317
-
1318
-
1319
MiR-15a-5p Knockdown up-Regulated ABCB1 Expression and Abated HNSCC Progression via the NF-κB Signaling Pathway
Published 2024“…</p> <p>Collectively, miR-15a-5p knockdown increased the ABCB1 level and abated the HNSCC progression <i>via</i> the NF-κB signaling pathway. …”
-
1320
Image_1_MICAL2 Facilitates Gastric Cancer Cell Migration via MRTF-A-Mediated CDC42 Activation.JPEG
Published 2021“…In addition, MICAL2-induced ROS generation contributed to the effect exerted by MICAL2 on MRTF-A nuclear translocation.</p><p>Conclusion: Together, these results provide evidence that MICAL2 facilitates gastric cancer cell migration via positive regulation of nuclear translocation of MRTF-A and subsequent CDC42 activation and MMP9 expression.…”